1,258 karma · joined December 30, 2008
https://www.jamroom.net/proxima
It's really designed for someone that is not a developer first. I built a MBaaS quite a few years ago, and Proxima was something I built on the side since I wanted an easy backend to power my own app. I also wanted someplace to do documentation, support, newsletters, etc. - so the idea with Proxima is that you can focus 100% on JUST your app and Proxima will handle your backend/website, etc.
Note too that it's not a SaaS - you would download and install it on your own server (although we do offer the hosting as well if interested). It's open source and free, so check it out if you're looking for something easy. Feel free to contact me as well if you have any questions.
Hope this helps!
https://eshop.macsales.com/shop/apple_laptop/batteries/MacBo...
"and miss all of the tremendous losers who picked php and got nothing for it"
certainly applies equally across all languages in my opinion.
Some companies are succeeding in spite of [insert language]. There are many, many users of [insert language], and we'd expect that there would be considerable variance, with some users doing awful (no traction, buggy sites, etc) and some hitting home runs (facebook). Because it's such a popular language, it will have users across this entire spectrum.
It's easy to cherry-pick the winners and miss all of the tremendous losers who picked [insert language] and got nothing for it.
These pharmaceutical companies are interested in one thing - making money, and therefore they need everyone to be a "customer" by taking one of their pills every day. This means even if there are simple (i.e. non patent-able) solutions to health problems, you won't see them pushing it - instead you'll see them ACTIVELY work to prevent it.
A good example is the recent case where these companies have spent $880 million in the last 10 years working against marijuana legalization, even though studies are showing that it can work as a good pain killer replacement for the more deadly opioids that they are eager to hand out.
See: http://bigstory.ap.org/article/4d69f4b41cbc475ca42f424524003...
"It was a very smart thing the sugar industry did because review papers, especially if you get them published in a very prominent journal, tend to shape the overall scientific discussion"
Has the acceptance policy for prominent journals improved that we're sure this is not happening now? I have suspicions that this is likely still happening more frequently then we might expect (i.e. pharmaceutical trials, etc.).